Board of Directors at its meeting held today recommended the Final Dividend for FY 2024-25
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.3 pts more than Nifty Smallcap 250 and 10.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals' Board of Directors, at a meeting held today, has recommended a Final Dividend for the financial year 2024-25. The specific dividend amount per share and the percentage were not disclosed in the headline. The dividend, once approved by shareholders, will be paid to eligible shareholders as per the record date to be announced. This indicates the company is returning value to its shareholders from its FY25 earnings.
Positive signal for shareholders as the company is sharing profits, though the magnitude of the dividend and its impact on stock price will depend on the final dividend amount and yield, which are not specified in this announcement.